Fatimah AlDosari, Shahad AlGhossen, Malka Alburaiki, Sireen Ar Shilbayeh, Nada AlBogami, Ammena Y Binsaleh, Nadia Al Mazrouei, Hayam A AlRasheed, Khlood M Aldossary, Omar Gammoh
{"title":"Description of schizophrenia treatment outcomes in Saudi Arabia: A preliminary pilot investigation.","authors":"Fatimah AlDosari, Shahad AlGhossen, Malka Alburaiki, Sireen Ar Shilbayeh, Nada AlBogami, Ammena Y Binsaleh, Nadia Al Mazrouei, Hayam A AlRasheed, Khlood M Aldossary, Omar Gammoh","doi":"10.1177/03000605251332443","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesSchizophrenia is a debilitating psychiatric illness that is often understudied due to stigma and cultural barriers. This report presents a clinical descriptive evaluation of patients with schizophrenia in Saudi Arabia, focusing on demographics, clinical information, and treatment efficacy and safety.MethodsThis single-center cross-sectional study included 42 patients on antipsychotics for at least 6 months, with a male-to-female ratio of 1:1 and a mean age of 36 years.ResultsMost patients were single (64.3%) and unemployed (51.2%), with 52.4% having only a high school education level. The median duration of antipsychotic treatment was 21.2 (1.7-227.5) months. Antipsychotic combination therapy was the most common intervention (59.5%). Efficacy results from the Positive and Negative Syndrome Scale showed complete remission in 4.8%, partial remission in 11.9%, moderate remission in 33.3%, and no improvement in 50% of the patients. Safety evaluation via the modified Simpson-Angus Scale indicated that 71.4% of the patients had normal scores, 26.2% experienced minimal movement disorders, and only 2.4% had clinically significant movement symptoms.ConclusionThis preliminary investigation examined the demographics and clinical features of patients with schizophrenia as well as efficacy and tolerability of relevant treatments. Larger studies are needed to understand this population comprehensively.</p>","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"53 4","pages":"3000605251332443"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035046/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605251332443","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
ObjectivesSchizophrenia is a debilitating psychiatric illness that is often understudied due to stigma and cultural barriers. This report presents a clinical descriptive evaluation of patients with schizophrenia in Saudi Arabia, focusing on demographics, clinical information, and treatment efficacy and safety.MethodsThis single-center cross-sectional study included 42 patients on antipsychotics for at least 6 months, with a male-to-female ratio of 1:1 and a mean age of 36 years.ResultsMost patients were single (64.3%) and unemployed (51.2%), with 52.4% having only a high school education level. The median duration of antipsychotic treatment was 21.2 (1.7-227.5) months. Antipsychotic combination therapy was the most common intervention (59.5%). Efficacy results from the Positive and Negative Syndrome Scale showed complete remission in 4.8%, partial remission in 11.9%, moderate remission in 33.3%, and no improvement in 50% of the patients. Safety evaluation via the modified Simpson-Angus Scale indicated that 71.4% of the patients had normal scores, 26.2% experienced minimal movement disorders, and only 2.4% had clinically significant movement symptoms.ConclusionThis preliminary investigation examined the demographics and clinical features of patients with schizophrenia as well as efficacy and tolerability of relevant treatments. Larger studies are needed to understand this population comprehensively.
期刊介绍:
_Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis.
As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible.
Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence.
Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements.
Print ISSN: 0300-0605